



## **Opthea to Participate in November Investor Conferences**

*Virtual Bell Potter Healthcare Conference, November 17, 2024*

*Jefferies London Healthcare Conference, November 19, 2024*

**Melbourne, Australia, and Princeton, NJ, US, November 4, 2024** -- Opthea Limited (ASX/NASDAQ: OPT, "Opthea", the "Company"), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that management will participate in two investor conferences in November 2024.

Conference details are as follows:

### **Bell Potter Healthcare Conference**

Presentation: Monday, November 17, 2024, 3:00 PM AEDT (Virtual)

Presenter: Frederic Guerard, PharmD, CEO, Opthea

The webcast will be accessible under "Events & Presentations" in the Investor Relations section of the Company's website, [www.opthea.com](http://www.opthea.com).

### **Jefferies London Healthcare Conference 2024**

One-on-One Meetings: Thursday, November 19, 2024

Participant: Frederic Guerard, PharmD, CEO, Opthea

### **About Opthea**

Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet needs in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).

Opthea's lead product candidate, sozinibercept, is being evaluated in two fully enrolled pivotal Phase 3 clinical trials (COAST, [NCT04757636](https://clinicaltrials.gov/ct2/show/study/NCT04757636), and ShORe, [NCT04757610](https://clinicaltrials.gov/ct2/show/study/NCT04757610)) for use in combination with standard-of-care anti-VEGF-A therapies to improve overall efficacy and deliver superior vision gains compared to standard-of-care anti-VEGF-A agents alone.

To learn more, visit our website at [www.opthea.com](http://www.opthea.com) and follow us on [X](#) and [LinkedIn](#).

Authorized for release to ASX by Frederic Guerard, PharmD, CEO

### **Investor Inquiries**

PJ Kelleher

LifeSci Advisors, LLC

Email: [pkelleher@lifesciadvisors.com](mailto:pkelleher@lifesciadvisors.com)

Phone: 617-430-7579

## **Media Inquiries**

Silvana Guerci-Lena  
NorthStream Global Partners  
Email: [silvana@nsgpllc.com](mailto:silvana@nsgpllc.com)

Join our email database to receive program updates:

Tel: +61 (0) 3 9826 0399, Email: [info@opthea.com](mailto:info@opthea.com) Web: [www.opthea.com](http://www.opthea.com)

Source: Opthea Limited